Tango Therapeutics, Inc. (NASDAQ: TNGX) is a Healthcare company (Biotechnology) with a market capitalization of $3.7B. The Maz Rating grades it against the other companies in its sector.
Tango Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $22.11, Tango Therapeutics, Inc. trades at 4.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -30.3%, return on invested capital of -22.6% and a free cash flow yield of -4.0%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 39.45. Over the past 52 weeks the share price ranged from $7.69 to $34.39, with a beta of 1.22.
Tango Therapeutics, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 13 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Tango Therapeutics, Inc. (TNGX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.86% / 30% · (Cash+Inv) / Mkt Cap (36m) 27.0% / 30% · Interest income / Revenue 715100000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.86% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 27.0% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 715100000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.86% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 27.0% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 715100000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 3.17% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 92.3% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 715100000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 3.02% / 33.33% · (Cash+ST Inv) / Total Assets 94.6% / 33.33% · (Cash+Recv) / Total Assets 94.6% / 33.33% · Interest income / Revenue 715100000.0% / 5% | Fail |
No. As of September 2026, Tango Therapeutics, Inc. (TNGX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Tango Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 715100000.0% of each dividend: Tango Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.